<DOC>
	<DOCNO>NCT00327327</DOCNO>
	<brief_summary>AMP-004 Phase 1b dose escalation trial design evaluate safety new drug imexon combination approve drug , gemcitabine , treatment patient previously untreated pancreatic cancer . The treatment consist dose imexon gemcitabine day 1 , 8 , 15 28 day cycle . The study design determine high dos two drug safely combine together .</brief_summary>
	<brief_title>Safety Study Imexon Plus Gemcitabine Untreated Pancreatic Adenocarcinoma</brief_title>
	<detailed_description />
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<criteria>Inoperable cancer pancreas . Blood cell count blood chemistry near normal range . Able perform activity daily live . A projected life expectancy least 2 month . If female , neither pregnant nursing . Willing use contraceptive prevent pregnancy . No serious illness . No active malignancy . No serious infection . No current drug therapy cancer steroid therapy . Prior radiation permit chemotherapy give radiation prevent relapse surgical removal disease . Prior chemotherapy metastatic disease . Brain metastasis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2010</verification_date>
</DOC>